[
  {
    "ts": null,
    "headline": "Cencora Stock: Analyst Estimates & Ratings",
    "summary": "Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=0f92852de47fc56d3c9203630d9bf880ccc64a227ffe9ef6ecda6acde7539f16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755092670,
      "headline": "Cencora Stock: Analyst Estimates & Ratings",
      "id": 136339394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=0f92852de47fc56d3c9203630d9bf880ccc64a227ffe9ef6ecda6acde7539f16"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Cencora’s Q2 Earnings Call",
    "summary": "Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market reacted negatively, reflecting investor concerns about slower growth in key areas. Management attributed the quarter’s outcomes to continued strength in U.S. Healthcare Solutions, particularly specialty distribution and higher utilization of pharmaceuticals, including GLP-1 products. However, CEO Robert Mauch and CFO James Cleary acknowledged moderating growth in GLP-1s and",
    "url": "https://finnhub.io/api/news?id=f9560c26e17b85974b7b40d64a3fefab9c1e1aca9dbf315924d289999052eb70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755063279,
      "headline": "The 5 Most Interesting Analyst Questions From Cencora’s Q2 Earnings Call",
      "id": 136328620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market reacted negatively, reflecting investor concerns about slower growth in key areas. Management attributed the quarter’s outcomes to continued strength in U.S. Healthcare Solutions, particularly specialty distribution and higher utilization of pharmaceuticals, including GLP-1 products. However, CEO Robert Mauch and CFO James Cleary acknowledged moderating growth in GLP-1s and",
      "url": "https://finnhub.io/api/news?id=f9560c26e17b85974b7b40d64a3fefab9c1e1aca9dbf315924d289999052eb70"
    }
  }
]